Company Overview

As a leader in the FcRn inhibitor technology, Immunovant, Inc is focused on enabling normal lives for people with autoimmune diseases. Immunovant is developing batoclimab (“IMVT-1401”) and IMVT-1402. Each of these assets is a novel, fully human anti-FcRn monoclonal antibody in development as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.

Stock Quote

Roivant Investor Day

Sep 28, 2022 11:00 am EDT

View Event

Email Alerts

Receive updates straight into your inbox

IR Contacts


Immunovant, Inc.
320 W 37th Street
6th Floor
New York, NY 10018

Investor Relations

Immunovant, Inc.
Chau Cheng, PhD, MBA
Investor Relations

Transfer Agent

Continental Stock Transfer & Trust Company, LLC
1 State Street
30th Floor
New York, NY 10004
T: 212-509-4000